Metmore G 2 mg/500 mg Tablet is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. This dual mechanism addresses both insulin deficiency and insulin resistance, providing an effective therapeutic approach for patients inadequately controlled with diet and exercise alone. Metmore G is prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. The tablet is typically administered once or twice daily with meals to minimize gastrointestinal side effects commonly associated with Metformin. Clinical monitoring of blood glucose levels, renal function, and potential adverse effects such as hypoglycemia, lactic acidosis, and gastrointestinal disturbances is essential during therapy. Dose adjustments may be necessary based on patient response and tolerability. Metmore G should be used cautiously in patients with renal impairment, hepatic dysfunction, or cardiovascular disease. It is contraindicated in patients with known hypersensitivity to its components or conditions predisposing to lactic acidosis.